Lawson, Kenny

No ORCID on file · 10 papers in corpus · active 2017-2021

Study types

  • article 6
  • other 4

Condition tags

  • endometriosis 10
  • chronic_pelvic_pain 8
  • dysmenorrhea 2
  • dyspareunia 2
article 2021
·doi:10.6084/m9.figshare.14462553.v1

Additional file 1.

article 2021
·doi:10.6084/m9.figshare.14462553

Additional file 1.

other 2021
·doi:10.6084/m9.figshare.c.5397666

Abstract Background Endometriosis is the presence of tissue similar to that of the endometrium outside the uterine cavity and is the most common cause of chronic pelvic pain. Current non-surgical treatments such as non-steroidal anti-inflam…

other 2021
·doi:10.6084/m9.figshare.c.5397666.v1

Abstract Background Endometriosis is the presence of tissue similar to that of the endometrium outside the uterine cavity and is the most common cause of chronic pelvic pain. Current non-surgical treatments such as non-steroidal anti-inflam…

article 2017
·doi:10.6084/m9.figshare.c.3820402_d1

Treatment of endometriosis related chronic pelvic pain: study protocol v3. (DOCX 74 kb)

article 2017
·doi:10.6084/m9.figshare.c.3820402_d1.v1

Treatment of endometriosis related chronic pelvic pain: study protocol v3. (DOCX 74 kb)

article 2017
·doi:10.6084/m9.figshare.c.3820402_d2.v1

SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 120 kb)

article 2017
·doi:10.6084/m9.figshare.c.3820402_d2

SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 120 kb)

other 2017
·doi:10.6084/m9.figshare.c.3820402.v1

Abstract Background Endometriosis is the most common cause of chronic pelvic pain worldwide. Non-surgical treatments are effective for only 30–50% of women and have a significant side effect burden that leads to high discontinuation rates. …

other 2017
·doi:10.6084/m9.figshare.c.3820402

Abstract Background Endometriosis is the most common cause of chronic pelvic pain worldwide. Non-surgical treatments are effective for only 30–50% of women and have a significant side effect burden that leads to high discontinuation rates. …